The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
The Neuroendocrine Tumor Research Foundation directs your individual donations to breakthrough scientific research. Since 2005, we have funded $37.6 million in research projects. The Neuroendocrine Research Foundation is a 501(c)(3) organization, so all donations are fully tax-deductible to the extent allowed by law. We are grateful to you for your generosity.
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
Dr. Po Hien Ear’s research involves growing NET spheroid clusters in large enough numbers to be used to screen the potential anti-tumor properties of hundreds of therapeutic compounds.
The Neuroendocrine Tumor Research Foundation (NETRF) has awarded $2.62 million in grants to advance research aimed at finding new and innovative treatments for neuroendocrine tumors
COVID forced NETRF’s annual Research Symposium to be held as a virtual meeting in November. Despite this change, the Symposium reached more researchers than ever
Early NETRF-funded research identifies a potential prognostic biomarker to help physicians predict neuroendocrine cancer outcomes.
NETRF’s Director of Research John Kanki, PhD, provides an update on the status of ongoing NETRF-funded research studies during COVID-19.
NETRF-funded research of miniature replicas of human organs is recognized with a Presidential Award for Basic Science at ENETS, a leading international meeting of NET scientists.
NETRF reports progress in the development of neuroendocrine tumor cell lines to help eliminate a decades-old obstacle in laboratory research. To stimulate progress in NET cell lines, NETRF established a Cell Line Prize, funded cell line research, and launched a collaboration with a nationally known research institute. Each of these initiatives has succeeded in establishing NET cell lines.
